Sponsored Content for Jennifer Chow

Chimeric Therapeutics' mission to beat cancer with its “natural killer” therapy has hit a new high point, with test-tube studies showing a 300 per cent increase in its ability to kill the pancreatic form of the insidious disease. The company's latest revelations also show its off-the-shelf “CLTX CAR NK” cell therapy recording a 260 per cent jump in killing ovarian cancer.

Chimeric Therapeutics says it is a step closer to unlocking treatment hope for patients suffering from the world's deadliest form of brain cancer after dosing its first patient as part of a phase-1B trial. The new trial comes on the back of positive survival results in the previous phase of testing as the company continues to tackle the devastating glioblastoma condition.

There is new survival hope for people diagnosed with brain cancer after a positive response from patients engaged in a Chimeric Therapeutics trial designed to monitor the efficacy of its promising cell therapy for glioblastoma. The cancer fighter says more than half of its participating patients extended median survival expectations up to 10 months, with two patients demonstrating survival beyond 14 months.

Cancer-fighting cell therapy company Chimeric Therapeutics has finished its fourth and final phase-1A dose escalation study at the City of Hope campus in the United States, with the successful treatment of a third clinical trial cohort using a scorpion venom derivative. The company's “CHM 1101” (CLTX CAR T) treatment is designed to treat patients with glioblastoma cancers.

Cancer fighter Chimeric Therapeutics has expanded its patent protection in Japan for certain cell therapy clinical and preclinical stage applications using chlorotoxin, which is derived from deathstalker scorpion venom. Management says the patents will expand the company's intellectual property portfolio and underpin important assets in its development pipeline. Japan has recently been dubbed the world's third-biggest pharmaceutical market.

Cell therapy cancer-fighter Chimeric Therapeutics is wasting no time on its mission to commercialise its novel potential treatment for glioblastoma. The ASX-listed company was given approval in April for a phase-1B clinical trial of the treatment, which employs the venom of the deathstalker scorpion. The first of multiple sites to enrol patients in the trial has now been revealed in the United States.

ASX-listed Chimeric Therapeutics has been granted an Indian patent for its CLTX CAR therapies as it closes in on getting similar protection in Israel for its cell treatment for patients with glioblastoma. The new patent in India covers particular applications of the company's technology which uses chlorotoxin, an amino acid peptide derived from deathstalker scorpion venom that it has utilised for its cancer fighting treatments.

Chimeric Therapeutics will showcase its cutting-edge cell therapy work before the world's leading cancer specialists in the United States in June, joining a select cohort picked from more than 6500 entries. The Melbourne biotech will outline its new clinical trial, designed to test its potential treatment for brain cancer, at the annual meeting of the American Society of Clinical Oncology.

ASX-listed cell therapy company Chimeric Therapeutics has moved a step closer to trialling its treatment for gastrointestinal and neuroendocrine cancers on humans following a successful meeting with the powerful American regulator the Food and Drug Administration (FDA). The company says the FDA's feedback was encouraging and its advice supports the company's proposed phase 1 trial for the cancer-fighting treatment.

Chimeric Therapeutics has successfully secured the manufacturing of a key tool for cell therapy targeting gastrointestinal and neuroendocrine tumours as the company gets set for a clinical trial. Management says by securing the supply of “viral vectors” it has successfully navigated one of the most critical and challenging components of the manufacture of its “CAR T” cell therapy Chimeric is now focused on advancing its treatment to a first phase clinical trial.

Chimeric Therapeutics has dosed its first patient in its phase 1B trial that is the first of its kind to test NK cells in combination with chemical compound Vactosertib in patients with advanced colorectal and blood cancers. The trial will be based on the company's CHM 0201 off-the-shelf cell platform that successfully demonstrated safety and efficacy during clinical trials completed at the Seidman Cancer Centre in Ohio last year.

ASX-listed cell therapy innovator Chimeric Therapeutics has secured an exclusive global licence from a leading American research university for a promising cancer-fighting treatment. The treatment centres on “natural killer” cells that occur organically in the human body and can recognise and kill cancer cells. Chimeric says the treatment continues to show promise after a clinical phase 1 trial earlier this year.

ASX-listed biotech company Chimeric Therapeutics has signed a sponsored research deal with Case Western Reserve University in the United States to develop the company's NK cell therapy portfolio to assist in its fight against cancer. One of Chimeric's key missions is to cure cancer, not simply slow its progress, by developing cutting-edge cell therapy treatments aimed at killing the molecules that drive cancer cells and promote metastases.

ASX-listed biotech and cancer fighter Chimeric Therapeutics has been granted patent protection in Japan for some of its novel cell therapy treatments – including one in a phase one trial and another at the pre-clinical stage. Chimeric management says the patents will expand the company's intellectual property portfolio underpinning important assets in its development pipeline. Japan is the world's third-largest pharmaceutical market.

Biotech company Chimeric Therapeutics has advanced its cutting-edge cancer-fighting work by expanding a licencing agreement with a top US university for breakthrough cancer treatment. The clinical-stage cell therapy company hopes the new agreement, through acquisition of critical know-how, will expedite its ambition to commercialise the treatment. Chimeric plans to use the treatment in a clinical study of patients with gastrointestinal cancers.

Cell immunotherapy company Chimeric Therapeutics will launch the first-ever trials of its patented CORE Natural Killer cells with two complementary smart drug therapies — one to stimulate the body's uptake of the treatment and the other to attack the defence mechanisms of colorectal cancer cells. The trials will be conducted at the UH Seidman Cancer Center in Ohio, USA.

Chimeric Therapeutics has cut out significant global supply chain problems facing the cell therapy industry by developing its own viral vector system to deliver its patented treatment for killing brain tumours. Viral vectors are tools commonly used by molecular biologists to deliver genetic material into cells.